{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:46:33Z","timestamp":1791647193829,"version":"4.3.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:p>\n                    Autosomal dominant polycystic kidney disease (ADPKD) is an important cause of ESRD for which there exists no approved therapy in the United States. Defective glucose metabolism has been identified as a feature of ADPKD, and inhibition of glycolysis using glucose analogs ameliorates aggressive PKD in preclinical models. Here, we investigated the effects of chronic treatment with low doses of the glucose analog 2-deoxy-\n                    <jats:sc>d<\/jats:sc>\n                    -glucose (2DG) on ADPKD progression in orthologous and slowly progressive murine models created by inducible inactivation of the\n                    <jats:italic toggle=\"yes\">Pkd1<\/jats:italic>\n                    gene postnatally. As previously reported, early inactivation (postnatal days 11 and 12) of\n                    <jats:italic toggle=\"yes\">Pkd1<\/jats:italic>\n                    resulted in PKD developing within weeks, whereas late inactivation (postnatal days 25\u201328) resulted in PKD developing in months. Irrespective of the timing of\n                    <jats:italic toggle=\"yes\">Pkd1<\/jats:italic>\n                    gene inactivation, cystic kidneys showed enhanced uptake of\n                    <jats:sup>13<\/jats:sup>\n                    C-glucose and conversion to\n                    <jats:sup>13<\/jats:sup>\n                    C-lactate. Administration of 2DG restored normal renal levels of the phosphorylated forms of AMP\u2013activated protein kinase and its target acetyl-CoA carboxylase. Furthermore, 2DG greatly retarded disease progression in both model systems, reducing the increase in total kidney volume and cystic index and markedly reducing CD45\u2013positive cell infiltration. Notably, chronic administration of low doses (100 mg\/kg 5 days per week) of 2DG did not result in any obvious sign of toxicity as assessed by analysis of brain and heart histology as well as behavioral tests. Our data provide proof of principle support for the use of 2DG as a therapeutic strategy in ADPKD.\n                  <\/jats:p>","DOI":"10.1681\/asn.2015030231","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T22:33:51Z","timestamp":1446590031000},"page":"1958-1969","source":"Crossref","is-referenced-by-count":179,"title":["2-Deoxy-d-Glucose Ameliorates PKD Progression"],"prefix":"10.1681","volume":"27","author":[{"given":"Marco","family":"Chiaravalli","sequence":"first","affiliation":[{"name":"Molecular Basis of Polycystic Kidney Disease Unit,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaline","family":"Rowe","sequence":"additional","affiliation":[{"name":"Molecular Basis of Polycystic Kidney Disease Unit,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Mannella","sequence":"additional","affiliation":[{"name":"Molecular Basis of Polycystic Kidney Disease Unit,"},{"name":"Biomolecular Nuclear Magnetic Resonance Unit, Division of Genetics and Cell Biology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Quilici","sequence":"additional","affiliation":[{"name":"Biomolecular Nuclear Magnetic Resonance Unit, Division of Genetics and Cell Biology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Canu","sequence":"additional","affiliation":[{"name":"Center for Experimental Imaging, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Division of Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Gurgone","sequence":"additional","affiliation":[{"name":"Division of Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Antunes","sequence":"additional","affiliation":[{"name":"Center for Experimental Imaging, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"D\u2019Adamo","sequence":"additional","affiliation":[{"name":"Division of Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Esposito","sequence":"additional","affiliation":[{"name":"Center for Experimental Imaging, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Musco","sequence":"additional","affiliation":[{"name":"Biomolecular Nuclear Magnetic Resonance Unit, Division of Genetics and Cell Biology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Boletta","sequence":"additional","affiliation":[{"name":"Molecular Basis of Polycystic Kidney Disease Unit,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2015,11,3]]},"reference":[{"key":"B1-20231016","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease.","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"B2-20231016","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","article-title":"Polycystic kidney disease.","volume":"60","author":"Harris","year":"2009","journal-title":"Annu Rev Med"},{"key":"B3-20231016","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1755-8417-2-6","article-title":"Emerging evidence of a link between the polycystins and the mTOR pathways.","volume":"2","author":"Boletta","year":"2009","journal-title":"PathoGenetics"},{"key":"B4-20231016","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/ki.1987.121","article-title":"Cyst formation and growth in autosomal dominant polycystic kidney disease.","volume":"31","author":"Grantham","year":"1987","journal-title":"Kidney Int"},{"key":"B5-20231016","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"B6-20231016","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B7-20231016","doi-asserted-by":"crossref","first-page":"40419","DOI":"10.1074\/jbc.M405079200","article-title":"Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype.","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J Biol Chem"},{"key":"B8-20231016","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease.","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"B9-20231016","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"B10-20231016","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B11-20231016","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"key":"B12-20231016","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/ndt\/gft521","article-title":"Defective metabolism in polycystic kidney disease: Potential for therapy and open questions.","volume":"29","author":"Rowe","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B13-20231016","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nm.3140","article-title":"Metabolic reprogramming in polycystic kidney disease.","volume":"19","author":"Priolo","year":"2013","journal-title":"Nat Med"},{"key":"B14-20231016","doi-asserted-by":"crossref","first-page":"e1003053","DOI":"10.1371\/journal.pgen.1003053","article-title":"Network analysis of a Pkd1-mouse model of autosomal dominant polycystic kidney disease identifies HNF4\u03b1 as a disease modifier.","volume":"8","author":"Menezes","year":"2012","journal-title":"PLoS Genet"},{"key":"B15-20231016","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1093\/hmg\/ddm299","article-title":"Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice.","volume":"16","author":"Lantinga-van Leeuwen","year":"2007","journal-title":"Hum Mol Genet"},{"key":"B16-20231016","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/nm1675","article-title":"A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1.","volume":"13","author":"Piontek","year":"2007","journal-title":"Nat Med"},{"key":"B17-20231016","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/dbio.2002.0597","article-title":"Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: A tool for temporally regulated gene activation\/inactivation in the mouse.","volume":"244","author":"Hayashi","year":"2002","journal-title":"Dev Biol"},{"key":"B18-20231016","doi-asserted-by":"crossref","first-page":"e7137","DOI":"10.1371\/journal.pone.0007137","article-title":"A novel mouse model reveals that polycystin-1 deficiency in ependyma and choroid plexus results in dysfunctional cilia and hydrocephalus.","volume":"4","author":"Wodarczyk","year":"2009","journal-title":"PLoS One"},{"key":"B19-20231016","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1681\/ASN.2011010084","article-title":"Macrophages promote cyst growth in polycystic kidney disease.","volume":"22","author":"Karihaloo","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B20-20231016","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.eplepsyres.2012.04.012","article-title":"Behavioral, cognitive, and safety profile of 2-deoxy-2-glucose (2DG) in adult rats.","volume":"101","author":"Ockuly","year":"2012","journal-title":"Epilepsy Res"},{"issue":"Suppl 8","key":"B21-20231016","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1528-1167.2008.01848.x","article-title":"Seizure suppression via glycolysis inhibition with 2-deoxy-D-glucose (2DG).","volume":"49","author":"Stafstrom","year":"2008","journal-title":"Epilepsia"},{"key":"B22-20231016","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.taap.2009.11.025","article-title":"Chronic ingestion of 2-deoxy-D-glucose induces cardiac vacuolization and increases mortality in rats.","volume":"243","author":"Minor","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"key":"B23-20231016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0165-0270(92)90124-V","article-title":"A new computer program for detailed off-line analysis of swimming navigation in the Morris water maze.","volume":"41","author":"Wolfer","year":"1992","journal-title":"J Neurosci Methods"},{"key":"B24-20231016","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0925-4439(92)90008-B","article-title":"High resolution proton magnetic resonance spectroscopy of cyst fluids from patients with polycystic kidney disease.","volume":"1138","author":"Foxall","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"B25-20231016","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","article-title":"A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.","volume":"71","author":"Raez","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B26-20231016","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/pros.21172","article-title":"Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies.","volume":"70","author":"Stein","year":"2010","journal-title":"Prostate"},{"key":"B27-20231016","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11306-006-0043-1","article-title":"Evaluation of metabolite extraction strategies from tissue samples using NMR metabolomics.","volume":"3","author":"Lin","year":"2007","journal-title":"Metabolomics"},{"key":"B28-20231016","first-page":"26","article-title":"A new approach to improving automated analysis of proton NMR.","volume":"23","author":"Cobas","year":"2010","journal-title":"Spectrosc Eur"},{"key":"B29-20231016","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-4598-8-41","article-title":"Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM).","volume":"8","author":"Fan","year":"2009","journal-title":"Mol Cancer"},{"key":"B30-20231016","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11306-010-0249-0","article-title":"Stable isotope resolved metabolomics of lung cancer in a SCID mouse model.","volume":"7","author":"Fan","year":"2011","journal-title":"Metabolomics"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201607000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:27:15Z","timestamp":1786130835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201607000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,3]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2015030231","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,3]]}}}